FDA Inspection 1014833 — Guangzhou Baiyunshan Pharmaceutical Co., Ltd.
The FDA completed an inspection of Guangzhou Baiyunshan Pharmaceutical Co., Ltd. on May 25, 2017 in Guangzhou. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). Product area: Drugs.
Inspection Details
- Classification
- Official Action Indicated (OAI) (OAI)
- End Date
- May 25, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Guangzhou (China)